hrp0092mte1 | Holistic Approach to the Individual with DSD | ESPE2019

Holistic Approach to the Individual with DSD

Cools Martine

Management of DSD is a sensitive area within the field of paediatric endocrinology. On the one hand, major progress has been made in amongst others understanding the molecular genetic background and the germ cell cancer risk of certain DSD conditions. On the other hand, practices that were common in the past, such as early genital surgery have become strongly criticised and controversial nowadays, leaving clinicians as well as patients and their families with a lot of question...

hrp0086p2-p396 | Gonads & DSD P2 | ESPE2016

Hypogonadotropic Hypogonadism in a Girl with 2p11.2–2q12.1 Duplication

Bianconi Martina , Scalini Perla , Maccora Ilaria , de Martino Maurizio , Megna Paolo , Stagi Stefano

Background: Patients with chromosome 2 pericentromeric duplication are rarely reported in literature.Objective and hypotheses: To describe a young girl with a congenital malformations syndrome, hypogonadotropic hypogonadism and impaired bone quality associated with a chromosome 2 pericentromeric duplication.Results: The proposita was born at 37th weeks of gestation from a twin pregnancy with a cesarean delivery presenting low birth...

hrp0086p2-p649 | Growth P2 | ESPE2016

A Case of Hypopituitarism in a Patient with Cantù Syndrome

Azzali Annachiara , La Spina Luisa , Gioe Daniela , Scalini Perla , Sandini Elena , Farri Martina , de Martino Maurizio , Stagi Stefano

Background: Cantù syndrome is a rare disorder characterized by congenital hypertrichosis, neonatal macrosomia, a distinct osteochondrodysplasia, and cardiomegaly. Other findings described are vascular abnormalities, pulmonary hypertension, generalized edema, mild learning disability and behavioral problems. Cantù syndrome is related to an heterozygous pathogenic variant in ABCC9 or KCNJ8, which can be inherited in an autosominal dominant manner or d...

hrp0084p3-954 | GH & IGF | ESPE2015

Long-Term Effects of GH Replacement Therapy on Hematopoiesis in GH Deficient Children

Esposito Andrea , De Martino Lucia , Barbieri Flavia , Rezzuto Martina , Improda Nicola , Cerbone Manuela , Capalbo Donatella , Salerno Mariacarolina

Background: Among their metabolic effects, GH and its mediator IGF1 have been reported to influence hematopoiesis. Indeed, GH/IGF1 axis promotes erythropoiesis and GH deficiency (GHD) has been associated with a normochromic and normocytic anemia both in adults and in children. In contrast, in vivo data on the effects of GH/IGF1 axis on leukocytes and platelets are scanty.Objective and hypotheses: To evaluate the effects of 4-years GH replacement...

hrp0095p1-39 | Diabetes and Insulin | ESPE2022

Case report: Suppression of gonadotropins with contraceptives in type A insulin resistance ameliorates virilizing insulin-induced hyperandrogenism

Raeder Helge , Engebretsen Martine , Førsvoll Jostein

Insulin-induced ovarian hyperstimulation and hyperandrogenization can cause virilization in children and adults. It rarely occurs in children and adolescents but when it does, it is usually caused by congenital adrenal hyperplasia or virilizing tumors. In very rare cases severe hyperandrogenism is caused by severe insulin resistance, either due to germline mutations in genes encoding the insulin receptor or proteins in downstream insulin signaling or due to insulin receptor an...

hrp0092p2-257 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2019

Physical Changes, Laboratory Parameters and Bone Mineral Density During Testosterone Treatment in Adolescents with Gender Dysphoria

Stoffers Iris , de Vries Martine , Hannema Sabine

Introduction: Although many adolescents with gender dysphoria (GD) are being treated with GnRH analogues (GnRHa) and gender affirming hormones there is a paucity of data on the effects and side effects of this treatment in this population. We aimed to study short-term outcome of testosterone treatment in male adolescents with GD.Methods: Sixty-two adolescents who had been treated with GnRHa, and subsequently with testost...

hrp0094yb2.1 | Year of Paediatric Endocrinology 2 | ESPE2021

DSD and Transgender - Updates 2021

Flueck Christa , Cools Martine , Nordenstrom Anna ,

In the past year, basic and genetic studies revealed again novel genes and mechanisms implicated in 46,XX and 46,XY DSD. The Fgf9-/- mouse model of human synostosis syndromes revealed an unexpected male-to-female sex reversal phenotype, so far not observed in humans. Specific heterozygous human WT1 gene variants located in the 4th zinc finger were found to cause 46,XX virilization due to (ovo-)testicular DSD, and the transcription factor...

hrp0084p2-310 | DSD | ESPE2015

Management of Gonads in Adults with Androgen Insensitivity: An International Survey

Maris Ellen , Looijenga L H J , Cools Martine

Background: Individuals with androgen insensitivity syndrome (AIS) have an increased risk for developing a germ cell cancer (GCC). The risk is low during childhood; therefore, gonads are commonly preserved until after puberty. Little is known about GCC development in AIS during adulthood. This question is particularly relevant as many adult AIS women decline gonadectomy.Objective and hypotheses: To gain insight in attitudes towards gonadectomy in various...

hrp0097p1-571 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2023

Early and long-term gender-affirming treatment does not alter final height in transgender youth

Ciancia Silvia , Klink Daniel , Craen Margarita , Cools Martine

Keywords: transgender, GnRH agonists, gender affirming hormones, final height, growth, pubertyBackground: Trans boys (TB) and trans girls (TG) who start medical gender-affirming treatment at Tanner stage 2-3 undergo early puberty suppression (ePS) with Gonadotropin-Releasing Hormone agonists (GnRHa) for several years and subsequently receive gender-affirming hormones (GAH), around 15-16 years. This treatment clearly inte...

hrp0084p2-507 | Pituitary | ESPE2015

Fanconi Anemia Endocrine Abnormalities – Case Report

Abreu Liliana , Martins Sofia , Marques Olinda

Background: Fanconi anemia (FA) is a rare, genetically and phenotypically heterogeneous, autosomal or x-linked recessive chromosome instability disorder characterized by multiple congenital anomalies, bone marrow failure, and increased susceptibility to specific malignancies. Other findings, including short stature, skin pigmentation, and endocrine abnormalities have been recognized, most notably GH deficiency (GHD), hypothyroidism, and hypogonadism.Case...